LINGO

Biogen Inc (NASDAQ: BIIB) announced that anti-Lingo failed both the primary and the secondary endpoints in its Phase 2 RRMS trial. Citi’s Robyn Karnauskas downgraded the rating on the company from Buy to Neutral, while lowering the price target from $345 to $295. Lingo Failure “While...